Analysts’ Weekly Ratings Changes for MannKind (MNKD)

MannKind (NASDAQ: MNKD) has recently received a number of price target changes and ratings updates:

• 7/8/2026 – MannKind had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – MannKind was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/5/2026 – MannKind was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/27/2026 – MannKind was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/6/2026 – MannKind was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/1/2026 – MannKind was given a new $11.00 price target by Wells Fargo & Company. They now have an “overweight” rating on the stock.

Insider Activity at MannKind

In other news, Director Steven B. Binder sold 16,940 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $3.29, for a total value of $55,732.60. Following the completion of the sale, the director directly owned 808,008 shares in the company, valued at $2,658,346.32. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.60% of the stock is owned by company insiders.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).